[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07254208":3,"trial-entities:NCT07254208":91,"trial-summary:NCT07254208":95},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":15,"phases":26,"enrollment_info":27,"interventions":30,"primary_outcomes":34,"secondary_outcomes":39,"sex":40,"minimum_age":41,"maximum_age":42,"healthy_volunteers":43,"eligibility_criteria":44,"std_ages":49,"locations":52,"central_contacts":84,"overall_officials":85,"references":86,"see_also_links":87},"NCT07254208","PBGENE-HBV-02","A Long-term Observational Study in Participants Who Have Received PBGENE-HBV","A Long-term Observational Study in Participants Who Have Received PBGENE-HBV, an In Vivo Gene Editing Investigational Product, in a Prior Clinical Study","ENROLLING_BY_INVITATION","2040-06","2026-04","2026-04-22","2025-12-25","Precision BioSciences, Inc.","INDUSTRY",null,"Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.","This is a LTFU observational study designed to evaluate the safety of PBGENE-HBV in participants previously exposed to PBGENE-HBV. This study protocol does not include administration of PBGENE-HBV.",[19],"Chronic HBV Infection",[21,22,23,24],"Hepatitis B Chronic","Gene Therapy","Gene Editing","PBGENE-HBV","OBSERVATIONAL",[],{"count":28,"type":29},45,"ESTIMATED",[31],{"type":32,"name":24,"description":33},"BIOLOGICAL","PBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.",[35],{"measure":36,"description":37,"timeFrame":38},"Safety to assess frequency, severity, and outcome of delayed adverse events","Delayed adverse events","15 years",[],"ALL","19 Years","80 Years",false,{"inclusion":45,"exclusion":46,"raw_text":48},[],[47],"N\u002FA","Inclusion Criteria:\n\n1. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study\n2. Participant, or their legally authorized representative, has provided signed informed consent.\n\nExclusion Criteria:\n\n* N\u002FA",[50,51],"ADULT","OLDER_ADULT",[53,62,68,76],{"facility":54,"city":55,"state":56,"zip":57,"country":58,"geoPoint":59},"Massachusetts General Hospital\u002FHarvard University","Boston","Massachusetts","02114","United States",{"lat":60,"lon":61},42.35843,-71.05977,{"facility":63,"city":64,"state":64,"country":64,"geoPoint":65},"Queen Mary Hospital, University of Hong Kong","Hong Kong",{"lat":66,"lon":67},22.27832,114.17469,{"facility":69,"city":70,"state":71,"zip":72,"country":71,"geoPoint":73},"ICS ARENSIA Exploratory Medicine SRL","Chisinau","Moldova","2025",{"lat":74,"lon":75},47.00902,28.85938,{"facility":77,"city":78,"state":79,"zip":80,"country":79,"geoPoint":81},"New Zealand Clinical Research","Auckland","New Zealand","1010",{"lat":82,"lon":83},-36.84853,174.76349,[],[],[],[88],{"label":89,"url":90},"Interventional Study PBGENE-HBV-01","https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06680232?term=NCT06680232&rank=1",{"nct_id":4,"conditions":92,"biomarkers":94},[93],"Chronic Hepatitis B",[],{"nct_id":4,"found":43,"summary":15,"prompt_version":15}]